Sublingual immunotherapy of allergic diseases

Expert Opinion on Drug Delivery

Volumn 3, Issue 5, 2006, Pages 599-612

  Warner Klein, Melanie ^a   Kalkbrenner, Frank ^a   Erb, Klaus J ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Allergy; Immune mechanisms; Subcutaneous immunotherapy; Sublingual immunotherapy

Indexed keywords

ALLERGEN; ALUMINUM HYDROXIDE; ANTIALLERGIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM PHOSPHATE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 5; RECOMBINANT ALLERGEN; RECOMBINANT HYPOALLERGENIC ALLERGEN DERIVATIVE; STEROID; UNCLASSIFIED DRUG; WASP VENOM;

ADJUVANT THERAPY; ALLERGIC ASTHMA; ALLERGIC DISEASE; ALLERGIC RHINITIS; ANAPHYLAXIS; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; BRONCHUS HYPERREACTIVITY; CHILD CARE; CLINICAL TRIAL; COCHRANE LIBRARY; COST EFFECTIVENESS ANALYSIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG SENSITIVITY; DRUG SENSITIZATION; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HAY FEVER; HOUSE DUST ALLERGY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; INFLAMMATORY CELL; INTERMETHOD COMPARISON; LANGERHANS CELL; LYMPHOCYTE ACTIVATION; META ANALYSIS; NONHUMAN; POLLEN ALLERGY; QUALITY OF LIFE; REGULATORY T LYMPHOCYTE; REVIEW; RHINOCONJUNCTIVITIS; RISK ASSESSMENT; SYMPTOM; SYSTEMATIC REVIEW; SYSTEMIC DISEASE; TH1 CELL; TH2 CELL; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, SUBLINGUAL; ALLERGENS; ANIMALS; ANTIBODY FORMATION; DESENSITIZATION, IMMUNOLOGIC; EOSINOPHILS; HUMANS; HYPERSENSITIVITY; TH1 CELLS; TH2 CELLS;

EID: 33748648784     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.3.5.599     Document Type: Review

References (181)

1. HAWRYLOWICZ CM, O'GARRA A: Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat. Rev. Immunol. (2005) 5:271-283.
2. BARNES PJ: New drugs for asthma. Nat. Rev. Drug Discov. (2004) 3:831-844.
3. BRYAN SA, LECKIE MJ, HANSEL TT, BARNES PJ: Novel therapy for asthma. Expert. Opin. Investig. Drugs (2000) 9(1):25-42.
4. NOON L: Prophylactic inoculation against hay fever. Lancet (1911) 1:1572-1573.
5. CANONICA GW, PASSALACQUA G: Noninjection routes for immunotherapy. J. Allergy Clin. Immunol. (2003) 111:437-448.
6. CRIMI E, VOLTOLINI S, TROISE C et al.: Local immunotherapy with Dermatophagoides extract in asthma. J. Allergy Clin. Immunol. (1991) 87:721-728.
7. BJORKSTEN B: Local immunotherapy is not documented for clinical use. Allergy (1994) 49:299-301.
8. PASSALACQUA G, ALBANO M, RUFFONI S et al.: Nasal immunotherapy to Parietaria: evidence of reduction of local allergic inflammation. Am. J. Respir. Crit. Care Med. (1995) 152:461-466.
9. DUBUSKE LM: Appropriate and inappropriate use of immunotherapy. Ann. Allergy Asthma Immunol. (2001) 87:56-67.
10. FINEGOLD I: Analyzing meta-analyses of specific immunotherapy in die treatment of asthma. Ann. Allergy Asthma Immunol. (2001) 87:33-37.
11. WILLIAMS AP, KRISHNA MT, FREW AJ: The safety of immunotherapy. Chn. Exp. Allergy (2004) 34:513-514.
12. MORENO C, CUESTA-HERRANZ J, FERNANDEZ-TAVORA L, ALVAREZ-CUESTA E: Immunotherapy safety: a prospective multi-centric monitoring study of biologically standardized therapeutic vaccines for allergic diseases. Clin. Exp. Allergy (2004) 34:527-531.
13. AGOSTINIS F, TELLARINI L, CANONICA GW, FALAGIANI P. PASSALACQUA G: Safety of sublingual immunotherapy with a monomeric allergoid in very young children. Allergy (2005) 60:133.
14. DAHL R, STENDER A, RAK S: Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy (2006) 61:185-190.
15. FREW AJ, SMITH HE: Sublingual immunorherapy. J. Allergy Clin. Immunol. (2001) 107:441-444.
16. WILSON DR, LIMA MT, DURHAM SR: Sublingual immunotherapy for allergic rhinitis: systematic review and mcta-analysis. Allergy (2005) 60:4-12.
17. GROSCLAUDE M, BOUILLOT P, ALT R et al.: Safety of various dosage regimens during induction of sublingual immunotherapy. A preliminary study. Int. Arch. Allergy Immunol. (2002) 129:248-253.
18. GIDARO GB, MARCUCCI F, SENSI L, INCORVAIA C, FRATI F, CIPRANDI G: The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin. Exp. Allergy (2005) 35:565-571.
19. BOUSQUET J, LOCKEY R, MALLING HJ: Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J. Allergy Clin. Immunol. (1998) 102:558-562.
20. FIOCCHI A, PAJNO G, LA GRUTTA S et al.: Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years. Ann. Allergy Asthma Immunol. (2005) 95:254-258.
21. RIENZO VD, MINELLI M, MUSARRA A et al.: Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin. Exp. Allergy (2005) 35:560-564.
22. GAMMERI E, ARENA A, D'ANNEO R, LA GRUTTA S: Safety and tolerability of ultra-Rush (20 minutes) sublingual immunotherapy in patients with allergic rhinitis and/or asthma. Allergol. Immunopathol. (2005) 33:142-144
23. ROSSI RE, MONASTEROLO G: A pilot study of feasibility of ultra-rush (20-25 minutes) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma. Int. J. Immunopathol. Pharmacol. (2005) 18:277-285.
24. TRIPODI S, DI RIENZO BA, BENINCORI N, SCALA G, PINGITORE G: Safety and tolerability of ultra-rush induction, less than one hour, of sublingual immunotherapy in children. Int. Arch. Allergy Immunol. (2006) 139:149-152.
25. PASSALACQUA G, GUERRA L, PASQUALI M, LOMBARDI C, CANONICA GW: Efficacy and safety of sublingual immunotherapy. Ann. Allergy Asthma Immunol. (2004) 93:3-12.
26. ANDRE C, VATRINET C, GALVAIN S, CARAT F, SICARD H: Safety of sublingual-swallow immunotherapy in children and adults. Int. Arch. Allergy Immunol. (2000) 121:229-234.
27. TILL SJ, FRANCIS JN, NOURI-ARIA K, DURHAM SR: Mechanisms of immunotherapy. J. Allergy Clin. Immunol. (2004) 113:1025-1034.
28. PAJNO GB, BARBERIO G, DE LUCA F, MORABITO L, PARMIANI S: Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin. Exp. Allergy (2001) 31:1392-1397.
29. DES ROCHES A, PARADIS L, MENARDO JL, BOUGES S, DAURES JP, BOUSQUET J: Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J. Allergy Clin. Immunol. (1997) 99:450-453.
30. HEDLIN G, HEILBORN H, LILJA G et al.: Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. J. Allergy Clin. Immunol. (1995) 96:879-885.
31. ARIANO R, KROON AM, AUGERI G, CANONICA GW, PASSALACQUA G: Long-term treatment with allergoid immunotherapy with Parietaria. Clinical and immunologic effects in a randomized, controlled trial. Allergy (1999) 54:313-319.
32. DURHAM SR, WALKER SM, VARGA EM et al.: Long-term clinical efficacy of grass-pollen immunotherapy. N. Engl. J. Med. (1999) 341:468-475.
33. BOUSQUET J, VAN CAUWENBERGE P, KHALTAEV N: Allergic rhinitis and its impact on asthma. J. Allergy Clin. Immunol. (2001) 108:S147-S334.
34. ABRAMSON MJ, PUY RM, WEINER JM: Allergen immunotherapy for asthma. Cochrane Database Syst. Rev. (2003):CD001186.
35. VARNEY VA, GAGA M, FREW AJ, ABER VR, KAY AB, DURHAM SR: Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. Br. Med. J. (1991) 302:265-269.
36. BOUSQUET J: Specific immunotherapy in asthma. Allergy (1999) 54(Suppl. 56):37-38.
37. BUCUR J, DREBORG S, EINARSSON R, LJUNGSTEDT-PAHLMAN I, NILSSON JE, PERSSON G: Immunotherapy with dog and cat allergen preparations in dog-sensitive and cat-sensitive asthmatics. Ann. Allergy (1989) 62:355-361.
38. HORST M, HEJJAOUI A, HORST V, MICHEL FB, BOUSQUET J: Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J. Allergy Clin. Immunol. (1990) 85:460-472.
39. SCADDING GK, BROSTOFF J: Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clin. Allergy (1986) 16:483-491.
40. MALLING HJ, ABREU-NOGUEIRA J, ALVAREZ-CUESTA E et al.: Local immunotherapy. Allergy (1998) 53:933-944.
41. WILSON DR, TORRES LI, DURHAM SR: Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst. Rev. (2003):CD002893.
42. BAHCECILER NN, ISIK U, BARLAN IB, BASARAN MM: Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr. Pulmonol. (2001) 32:49-55.
43. BOUSQUET J, SCHEINMANN P, GUINNEPAIN MT et al.: Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy (1999) 54:249-260.
44. CAFFARELLI C, SENSI LG, MARCUCCI F, CAVAGNI G: Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial. Allergy (2000) 55:1142-1147.
45. CLAVEL R, BOUSQUET J, ANDRE C: Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis. Allergy (1998) 53:493-498.
46. FELIZIANI V, LATTUADA G, PARMIANI S, DALL'AGLIO PP: Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. Allergol. Immunopathol. (1995) 23:224-230.
47. GIOVANE AL, BARDARE M, PASSALACQUA G et al.: A three-year double-blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in paediatric patients. Clin. Exp. Allergy (1994) 24:53-59.
48. GUEZ S, VATRINET C, FADEL R, ANDRE C: House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study. Allergy (2000) 55:369-375.
49. HIRSCH T, SAHN M, LEUPOLD W: Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children. Pediatr. Allergy Immunol. (1997) 8:21-27.
50. HORAK F, STUBNER P, BERGER UE, MARKS B, TOTH J, JAGER S: Immunotherapy with sublingual birch pollen extract. A short-term double-blind placebo study. J. Investig. Allergol. Clin. Immunol. (1998) 8:165-171.
51. HORDIJK GJ, ANTVELINK JB, LUWEMA RA: Sublingual immunotherapy with a standardised grass pollen extract; a double-blind placebo-controlled study. Allergol. Immunopathol. (1998) 26:234-240.
52. LA ROSA M, RANNO C, ANDRE C, CARAT F, TOSCA MA, CANONICA GW: Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. (1999) 104:425-432.
53. LIMA MT, WILSON D, PITKIN L et al.: Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin. Exp. Allergy (2002) 32:507-514.
54. PAJNO GB, MORABITO L, BARBERIO G, PARMIANI S: Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy (2000) 55:842-849.
55. PASSALACQUA G, ALBANO M, FREGONESE L et al.: Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mice-induced rhinoconjunctivitis. Lancet (1998) 351:629-632.
56. PASSALACQUA G, ALBANO M, RICCIO A et al.: Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: a double-blind, placebo-controlled trial. J. Allergy Clin. Immunol. (1999) 104:964-968.
57. PRADALIER A, BASSET D, CLAUDEL A et al.: Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis. Allergy (1999) 54:819-828.
58. PURELLO-D'AMBROSIO F, GANGEMI S, ISOLA S et al.: Sublingual immunotherapy- a double-blind, placebo-controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both. Allergy (1999) 54:968-973.
59. SABBAH A, HASSOUN S, LE SELLIN J, ANDRE C, SICARD H: A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy (1994) 49:309-313.
60. TARI MG, MANCINO M, MONTI G: Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. AlLergol. Immunopathol. (1990) 18:277-284.
61. TROISE C, VOLTOLINI S, CANESSA A, PECORA S, NEGRINI AC: Sublingual immunotherapy in Parietaria pollen-induced rhinitis: a double-blind study. J. Investig. Allergol. Clin. lmmunol. (1995) 5:25-30.
62. VOURDAS D, SYRIGOU E, POTAMIANOU P et al.: Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy (1998) 53:662-672.
63. ARIANO R, PANZANI RC, MISTRELLO G: Efficacy of sublingual coseasonal immunotherapy with a monomeric allergoid in Cupressaceae pollen allergy-preliminary data. Allerg. Immunol. (2005) 37:103-108.
64. VOLTOLINI S, MODENA P, MINALE P et al.: Sublingual immunotherapy in tree pollen allergy. Double-blind, placebo-controlled study with a biologically standardised extract of three pollens (alder, birch and hazel) administered by a rush schedule. Allergol. Immunopathol. (2001) 29:103-110.
65. MALLING HJ: Is sublingual immunotherapy clinically effective? Curr. Opin. Allergy Clin. Immunol. (2002) 2:523-531.
66. MUNGAN D, MISIRLIGIL Z, GURBUZ L: Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma-a placebo controlled study. Ann. Allergy Asthma Immunol. (1999) 82:485-490.
67. TONNEL AB, SCHERPEREEL A, DOUAY B et al.: Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. Allergy (2004) 59:491-497.
68. MARCUCCI F, SENSI LG, CAFFARELLI C et al.: Low-dose local nasal immunotherapy in children with perennial allergic rhinitis due to Dermatophagoides. Allergy (2002) 57:23-28.
69. ROLINCK-WERNINGHAUS C, WOLF H, LIEBKE C et al: A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen. Allergy (2004) 59:1285-1293.
70. NOVEMBRE E, GALLI E, LANDI F et al.: Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. (2004) 114:851-857.
71. SOPO SM, MACCHIAIOLO M, ZORZI G, TRIPODI S: Sublingual immunotherapy in asthma and rhinoconjunctivitis; systematic review of paediatric literature. Arch. Dis. Child (2004) 89:620-624.
72. PHAM-THI N, DE BLIC J, SCHEINMANN P: Sublingual immunotherapy in the treatment of children. Allergy (2006) 61 (Suppl. 81):7-10.
73. SCHADLICH PK, BRECHT JG: Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics (2000) 17:37-52.
74. MOLLER C, DREBORG S, FERDOUSI HA et al.: Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J. Allergy Clin. Immunol. (2002) 109:251-256.
75. ENG PA, BORER-REINHOLD M, HEIJNEN IA, GNEHM HP: Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy (2006) 61:198-201.
76. DI RIENZO V, MARCUCCI F, PUCCINELLI P et al.: Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin. Exp. Allergy (2003) 33:206-210.
77. KHINCHI MS, OULSEN LK, CARAT F, ANDRE C, HANSEN AB, MALLING HJ: Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy (2004) 59:45-53.
78. QUIRINO T, IEMOLI E, SICILIANI E, PARMIANI S, MILAZZO F: Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Clin. Exp. Allergy (1996) 26:1253-1261.
79. MALLING HJ: Comparison of the clinical efficacy and safety of subcutaneous and sublingual immunotherapy: methodological approaches and experimental results. Cury. Opin. Allergy Clin. Immunol. (2004) 4:539-542.
80. BERNARDIS P, AGNOLETTO M, PUCCINELLI P, PARMIANI S, POZZAN M: Injective versus sublingual immunotherapy in Alternaria tenuis allergic patients. J. Investig. Allergol. Clin. Immunol. (1996) 6:55-62.
81. PIAZZA I, BIZZARO N: Humoral response to subcutaneous, oral, and nasal immunotherapy for allergic rhinitis due to Dermatophagoides pteronyssinus. Ann. Allergy (1993) 71:461-469.
82. EINARSSON R, RENCK B, TAUDORF E: In vitro studies of degradation of birch and timothy pollen allergen preparations by human duodenal juice. Allergy (1988) 43:469-472.
83. BUCKLE FG, COHEN AB: Nasal mucosal hyperpermeabilicy to macromolecules in atopic rhinitis and extrinsic asthma. J. Allergy Clin. Immunol. (1975) 55:213-221.
84. PASSALACQUA G, ALTRINETTI V, MARIANI G et al.: Pharmacokinetics of radiolabelled Par j 1 administered intranasally to allergic and healthy subjects. Clin. Exp. Allergy (2005) 35:880-883.
85. MISTRELLO G, RAPISARDA G, FALAGIANI P: Detection of IgE-binding activity in serum after intranasal treatment of normal rabbits with P. judaica extract. Allergy (1991) 46:52-58.
86. BAGNASCO M, PASSALACQUA G, VILLA G et al.: Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers. Clin. Exp. Allergy (2001) 31:54-60.
87. BAGNASCO M, ALTRINETTI V, PESCE G et al.: Pharmacokinetics of Der p 2 allergen and derived monomeric allergoid in allergic volunteers. Int. Arch. Allergy Immunol. (2005) 138:197-202.
88. BAGNASCO M, MARIANI G, PASSALACQUA G et al.: Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings. J. Allergy Clin. Immunol. (1997) 100:122-129.
89. WALKER GF, LANGOTH N, BERNKOP-SCHNURCH A. Peptidase activity on the surface of the porcine buccal mucosa. Int. J. Pharm. (2002) 233:141-147.
90. IGEA JM, CUEVAS M, LAZARO M, QUIRCE S, CUESTA J: Susceptibility of a grass-pollen oral immunotherapy extract to the saliva and gastric fluid digestive process. Allergol. Immunopathol. (1994) 22:55-59.
91. BURASTERO S: Regarding Gidaro GB, Marcucci F, Sensi L, Incorvaia C, Frati E, Ciprandi G. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy 2005; 35:565-71.
92. BURASTERO S: Clin. Exp. Allergy (2005) 35:1407-1408.
93. EWBANK PA, MURRAY J, SANDERS K, CURRAN-EVERETT D, DRESKIN S, NELSON HS: A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract. J. Allergy Clin. Immunol. (2003) 111:155-161.
94. WERFEL T, BREUER K, RUEFF F et al.: Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy (2006) 61:202-205.
95. DIDIER A, MELAC M, COMBEBIAS A, ANDRE C: Efficacy and safety of sublingual immunotherapy [SLIT] tablets in grass pollen rhinoconjunctivitis [abstract]. J Allergy Clin. Immunol. (2006) 117:721.
96. MOINGEON P BATARD T, FADEL R, FRATI F, SIEBER J, OVERTVELT L: Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy (2006) 61:151-165.
97. WILLIAMSON E, O'MALLEY JM, VINEY JL: Visualizing the T-cell response elicited by oral administration of soluble protein antigen. Immunology (1999) 97:565-572.
98. ALLAM JP, NIEDERHAGEN B, BUCHELER M et al.: Comparative analysis of nasal and oral mucosa dendritic cells. Allergy (2006) 61:166-172.
99. ANJUERE F, MARTIN P, FERRERO I et al.: Definition of dendritic cell subpopulations present in the spleen, Peyer's patches, lymph nodes, and skin of the mouse. Blood (1999) 93:590-598.
100. HEUFLER C, KOCH F, SCHULER G; Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J. Exp. Med. (1988) 167:700-705.
101. HOLT PG, OLIVER J, BILYK N et al.: Downregulation of the antigen presenting cell function(s) of pulmonary dendritic cells in vivo by resident alveolar macrophages. J. Exp. Med. (1993) 177:397-407.
102. LIU LM, MACPHERSON GG: Antigen processing: cultured lymph-borne dendritic cells can process and present native protein antigens. Immunology (1995) 84:241-246.
103. O'DOHERTY U, STEINMAN RM, PENG M et al.: Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte-conditioned medium. J. Exp. Med. (1993) 178:1067-1076.
104. HASSEUS B, JONTELL M, BERGENHOLTZ G, EKLUND C, DAHLGREN UI: Langerhans cells from oral epithelium are more effective in stimulating allogeneic T-cells in vitro than Langerhans cells from skin epithelium. J. Dent. Res. (1999) 78:751-758.
105. ALLAM JP, NOVAK N, FUCHS C et al.: Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive FcepsilonRI expression. J. Allergy Clin. Immunol. (2003) 112:141-148.
106. HASSEUS B, JONTELL M, BERGENHOLTZ G, DAHLGREN UI: Langerhans cells from human oral epithelium are more effective at stimulating allogeneic T cells in vitro than Langerhans cells from skin. Clin. Exp. Immunol. (2004) 136:483-489.
107. WOLVERS DA, COENEN-DE ROO CJ, MEBIUS RE et al.: Intranasally induced immunological tolerance is determined by characteristics of the draining lymph nodes: studies with OVA and human cartilage gp-39. J. Immunol. (1999) 162:1994-1998.
108. LICHTENSTEIN LM, ISHIZAKA K, NORMAN PS, SOBOTKA AK, HILL BM: IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J. Clin. Invest (1973) 52:472-482.
109. PIERSON-MULLANY LK, JACKOLA D, BLUMENTHAL M, ROSENBERG A: Altered allergen binding capacities of Amb a 1-specific IgE and IgG4 from ragweed-sensitive patients receiving immunotherapy. Ann. Allergy Asthma Immunol. (2000) 84:241-243.
110. DJURUP R, MALLING HJ: High IgG4 antibody level is associated with failure of immunotherapy with inhalant allergens. Clin. Allergy (1987) 17:459-468.
111. HAKANSSON L, HEINRICH C, RAK S, VENGE P: Activation of B-lymphocytes during pollen season. Effect of immunotherapy. Clin. Exp. Allergy (1999) 28:791-798.
112. GARCIA BE, SANZ ML, GATO JJ, FERNANDEZ J, OEHLING A: IgG4 blocking effect on the release of antigen-specific histamine. J. Investig. Allergol. Clin. Immunol. (1993) 3:26-33.
113. MOTHES N, HEINZKILL M, DRACHENBERG KJ et al.: Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin. Exp. Allergy (2003) 33:1198-1208.
114. SVENSON M, JACOBI HH, BODTGER U, POULSEN LK, RIENECK K, BENDTZEN K: Vaccination for birch pollen allergy. Induction of affinity-matured or blocking IgG antibodies does not account for the reduced binding of IgE to Bet v 1. Mol. Immunol. (2003) 39:603-612.
115. GEHLHAR K, SCHLAAK M, BECKER W, BUFE A: Monitoring allergen immunotherapy of pollen-allergic patients: the ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome. Clin. Exp. Allergy (1999) 29:497-506.
116. WACHHOLZ PA, DURHAM SR: Induction of 'blocking' IgG antibodies during immunotherapy. Clin. Exp. Allergy (2003) 33:1171-1174.
117. FLICKERS, VALENTA R: Renaissance of the blocking antibody concept in type I allergy. Int. Arch. Allergy Immunol. (2003) 132:13-24.
118. JAKOBSEN CG, BODTGER U, POULSEN LK, ROGGEN EL: Vaccination for birch pollen allergy: comparison of the affinities of specific immunoglobulins E, G1 and G4 measured by surface plasmon resonance. Clin. Exp. Allergy (2005) 35:193-198.
119. KILDSGAARD J, BRIMNES J, JACOBI H, LUND K: Sublingual immunotherapy in sensitised mice. Abstracts of the World Allergy Congress Munich 2005. Allergy Clin. Immunol. Int. J. World Allergy Org. Suppl. 1 (2005):500.
120. BARCECILER NN, ARIKAN C, TAYLOR A et al.: Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int. Arch. Allergy Immunol. (2005) 136:287-294.
121. + T cells by inhibiting serum-IgE-facilitated allergen presentation. J. Immunol. (1999) 163:2944-2952.
122. VAN NEERVEN RJ, ARVIDSSON M, IPSEN H, SPARHOLT SH, RAK S, WURTZEN PA: A double-blind, placebo-controlled birch allergy vaccination study: inhibition of CD23-mediated serum-immunoglobulin E-facilitated allergen presentation. Clin. Exp. Allergy (2004) 34:420-428.
123. DUCHATEAU J, MICHILS A, MICHEL O, BARAS L: Mite allergy is associated with a specific profile of IgG epitopes recognized on antigen p1 of Dermatophagoides pteronyssinus. Clin. Exp. Allergy (1997) 27:296-305.
124. MICHILS A, VERVIER I, CHOUFANI G, GOSSART B, DUCHATEAU J: Relationship between allergic status and specificity of IgG antibody to inhaled allergens: the grass pollen model. Clin. Exp. Allergy (1999) 29:832-839.
125. DUCHATEAU J, MICHILS A, LAMBERT J, GOSSART B, CASIMIR G: Anti-β lactoglobulin IgG antibodies bind to a specific profile of epitopes when patients are allergic to cow's milk proteins. Clin. Exp. Allergy (1998) 28:824-833.
126. MICHILS A, BALDASSARRE S, LEDENT C, MAIRESSE M, GOSSART B, DUCHATEAU J: Early effect of ultrarush venom immunotherapy on the IgG antibody response. Allergy (2000) 55:455-462.
127. WILSON DR, IRANI AM, WALKER SM et al.: Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin. Exp. Allergy (2001) 31:1705-1713.
128. WILSON DR, NOURI-ARIA KT, WALKER SM et al.: Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. J. Allergy Clin. Immunol. (2001) 107:971-976.
129. POLOSA R, LI GF, MANGANO G et al.: Effect of immunotherapy on asthma progression, BHR and sputum eosinophils in allergic rhinitis. Allergy (2004) 59:1224-1228.
130. POLOSA R, LI GF, MANGANO G, MASTRUZZO C, PISTORIO MP, CRIMI N: Monitoring of seasonal variability in bronchial hyper-responsiveness and sputum cell counts in non-asthmatic subjects with rhinitis and effect of specific immunotherapy. Clin. Exp. Alleygy (2003) 33:873-881.
131. DURHAM SR, VARNEY VA, GAGA M et al.: Grass pollen immunotherapy decreases the number of mast cells in the skin. Clin. Exp. Allergy (1999) 29:1490-1496.
132. MONTESEIRIN J, BONILLA I, CAMACHO J, CONDE J, SOBRINO F: Elevated secretion of myeloperoxidase by neutrophils from asthmatic patients: the effect of immunotherapy. J. Allergy Clin. Immunol. (2001) 107:623-626.
133. FURIN MJ, NORMAN PS, CRETICOS PS et al.: Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. J. Allergy Clin. Immunol. (1991) 88:27-32.
134. FANTA C, BOHLE B, HIRT W et al.: Systemic immunological changes induced by administration of grass pollen allergens via the oral mucosa during sublingual immunotherapy. Int. Arch. Allergy Immunol. (1999) 120:218-224.
135. MARCUCCI F, SENSI L, FRATI F et al.: Sublingual tryptase and ECP in children treated with grass pollen sublingual immunotherapy (SLIT): safety and immunologic implications. Allergy (2001) 56:1091-1095.
136. MARCUCCI F, SENSI L, FRATI F et al.: Effects on inflammation parameters of a double-blind, placebo controlled one-year course of SLIT in children monosensitized to mites. Allergy (2003) 58:657-662.
137. SILVESTRI M, SPALLAROSSA D, BATTISTINI E et al.: Changes in inflammatory and clinical parameters and in bronchial hyperreactivity asthmatic children sensitized to house dust mites following sublingual immunotherapy. J. Investig. Allergol. Clin. Immunol. (2002) 12:52-59.
138. + T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model. J. Exp. Med. (1995) 182:1579-1584.
139. + interleukin-10+ T cells expressing peripheral tissue trafficking markers. Clin. Exp. Allergy (2004) 34:1209-1219.
140. BENJAPONPITAK S, ORO A, MAGUIRE P, MARINKOVICH V, DEKRUYFF RH, UMETSU DT: The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy. J. Allergy Clin. Immunol. (1999) 103:468-475.
141. + T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-γ. J. Allergy Clin. Immunol. (1996) 97:1356-1365.
142. H1 in T-cell clones specific for Ph1 p 1, a major grass pollen allergen. Clin. Exp. Allergy (1997) 27:1007-1015.
143. FAITH A, RICHARDS DF, VERHOEF A, LAMB JR, LEE TH, HAWRYLOWICZ CM: Impaired secretion ofinterleukin-4 and interleukin-13 by allergen-specific T cells correlates with defective nuclear expression of NF-AT2 and jun B: relevance to immunotherapy. Clin. Exp. Allergy (2003) 33:1209-1215.
144. GABRIELSSON S, SODERLUNDA, PAULIE S, VAN DER POUW KRAAN TC, TROYE-BLOMBERG M, RAK S: Specific immunotherapy prevents increased levels of allergen-specific IL-4- and IL-13-producing cells during pollen season. Allergy (2001) 56:293-300.
145. H2 lymphocytes from atopic patients treated with immunotherapy undergo rapid apoptosis after culture with specific allergens. J Allergy Clin. Immunol. (2001) 107:647-653.
146. HAMID QA, SCHOTMAN E, JACOBSON MR, WALKER SM, DURHAM SR: Increases in IL- 12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J. Allergy Clin. Immunol. (1997) 99:254-260.
147. MAJORI M, CAMINATI A, CORRADI M, BRIANTI E, SCARPA S, PESCI A: T-cell cytokine pattern at three time points during specific immunotherapy for mite-sensitive asthma. Clin. Exp. Allergy (2000) 30:341-347.
148. MEISSNER N, KOCHS S, COUTELLE J et al.: Modified T-cell activation pattern during specific immunotherapy (SIT) in cat-allergic patients. Clin. Exp. Allergy (1999) 29:618-625.
149. O'BRIEN RM, BYRON KA, VARIGOS GA, THOMAS WR: House dust mite immunotherapy results in a decrease in Der p 2-specific IFN-γ and IL-4 expression by circulating T lymphocytes. Clin. Exp. Allergy (1997) 27:46-51.
150. OLDFIELD WL, LARCHE M, KAY AB: Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet (2002) 360:47-53.
151. + T cells from allergic individuals. J. Exp. Med. (1993) 178:2123-2130.
152. VAN BEVER HP, VEREECKE IF, BRIDTS CH, DE CLERCK LS, STEVENS WJ: Comparison between the in vitro cytokine production of mononuclear cells of young asthmatics with and without immunotherapy (IT). Clin. Exp. Allergy (1998) 28:943-949.
153. VARNEY VA, HAMID QA, GAGA M et al.: Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J. Clin. Invest. (1993) 92:644-651.
154. LAAKSONEN K, JUNIKKA M, LAHESMAA R, TERHO EO, SAVOLAINEN J: In vitro allergen-induced mRNA expression of signaling lymphocytic activation molecule by PBMC of patients with allergic rhinitis is increased during specific pollen immunotherapy. J. Allergy Clin. Immunol. (2003) 112:1171-1177.
155. H2 cytokine ratios. Immunology (2002) 105:56-62.
156. BELLINGHAUSEN I, METZ G, ENK AH, CHRISTMANN S, KNOP J, SALOGA J: Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur. J. Immunol. (1997) 27:1131-1139.
157. CIPRANDI G, FENOGLIO D, CIRILLO I et al.: Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report. Ann. Allergy Asthma Immunol. (2005) 95:38-44.
158. FENOGLIO D, PUPPO F, CIRILLO I et al.: Sublingual specific immunotherapy reduces PBMC proliferations. Allerg. Immunol. (2005) 37:147-151.
159. IPPOLITI F, DE SANTIS W. VOLTERRANI A et al.: Immunomodulation during sublingual therapy in allergic children. Pediatr. Allergy Immunol. (2003) 14:216-221.
160. ROLINCK-WERNINGHAUS C, KOPP M, LIEBKE C, LANGE J, WAHN U, NIGGEMANN B: Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen. Int. Arch. Allergy Immunol. (2005) 136:134-141.
161. + T cells selectively kill B lymphocytes. Blood (2006) 107:3925-32.
162. + T cells by grass pollen immunotherapy. J. Allergy Clin. Immunol. (2003) 111:1255-1261.
163. JUTEL M, AKDIS M, BUDAK F et al.: IL-10 and TGF-β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur. J. Immunol. (2003) 33:1205-1214.
164. SCHMIDT-WEBER CB, BLASER K: T-cell tolerance in allergic response.
165. SAMSOM JN, VAN BERKEL LA, VAN HELVOORT JM et al.: Fc γ RIIB regulates nasal and oral tolerance: a role for dendritic cells. J. Immunol. (2005) 174:5279-5287.
166. AKDIS CA, JOSS A, AKDIS M, FAITH A, BLASER K: A molecular basis for T cell suppression by IL-10: CD28-associated IL-10 receptor inhibits CD28 tyrosine phosphorylation and phosphatidylinositol 3-kinase binding. FASEB J. (2000) 14:1666-1668.
167. H2 cytokine production from asthmatic bronchial tissue: role for alpha-beta, but not gamma-delta, T cells. J. Immunol. (1999) 163:6283-6291.
168. LARCHE M, TILL SJ, HASELDEN BM et al.: Costimulation through CD86 is involved in airway antigen-presenting cell and T cell responses to allergen in atopic asthmatics. J. Immunol. (1998) 161:6375-6382.
169. VAN NEERVEN RJ, VAN DE POL MM, VAN DER ZEE JS, STIEKEMA FE, DE BOER M, KAPSENBERG ML: Requirement of CD28-CD86 costimulation for allergen-specific T cell proliferation and cytokine expression. Clin. Exp. Allergy (1998) 28:808-816.
170. KRETSCHMER K, APOSTOLOU I, HAWIGER D, KHAZAIE K, NUSSENZWEIG MC, VON BOEHMER H: Inducing and expanding regulatory T cell populations by foreign antigen. Nat. Immunol. (2005) 6:1219-1227.
171. APOSTOLOU I, VON BOEHMER H: In vivo instruction of suppressor commitment in naive T cells. J. Exp. Med. (2004) 199:1401-1408.
172. FARIA AM, MARON R, FICKER SM, SLAVIN AJ, SPAHN T, WEINER HL: Oral tolerance induced by continuous feeding: enhanced up-regulation of transforming growth factor-β/interleukin-10 and suppression of experimental autoimmune encephalomyelitis. J. Autoimmun. (2003) 20:135-145.
173. MARSHALL JD, ABTAHI S, EIDEN JJ et al.: Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H) 1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy. J. Allergy Clin. Inimunol. (2001) 108:191-197.
174. SIMONS FE, SHIKISHIMA Y, VAN NEST G, EIDEN JJ, HAYGLASS KT. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J. Allergy Clin. Immunol. (2004) 113:1144-1151.
175. ARIKAN C, BAHCECILER NN, DENIZ G et al.: Bacillus Calmette-Guerin-induced interleukin-12 did not additionally improve clinical and immunologic parameters in asthmatic children treated with sublingual immunotherapy. Clin. Exp. Allergy (2004) 34:398-405.
176. VAJDY M, SINGH M: The role of adjuvants in the development of mucosal vaccines. Expert. Opin. Biol. Ther. (2005) 5(7):953-965.
177. MOINGEON P: Sublingual immunotherapy: from biological extracts to recombinant allergens. Allergy (2006) 61(Suppl. 81):15-19.
178. GAFVELIN G, THUNBERG S, KRONQVIST M et al.: Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Int. Arch. Allergy Immunol. (2005) 138:59-66.
179. LINHART B, HARTL A, JAHN-SCHMID B et al.: A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. J. Allergy Clin. Immunol. (2005) 115:1010-1016.
180. REISINGER J, HORAK F, PAULI G et al.: Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J. Allergy Clin. Immunol. (2005) 116:347-354.
181. PAJNO GB: Allergen immunotherapy in early childhood: between Scylla and Charybdis! Clin. Exp. Allergy (2005) 35:551-553.